ScreenPoint Medical Raises $16M for AI Breast Cancer Detection

ScreenPoint Medical Locks In $16M to Reshape the Future of AI-Powered Breast Cancer Care

Breast cancer continues to be one of the most diagnosed cancers among women worldwide, and early detection remains the single most powerful tool in improving survival outcomes. Against that backdrop, a Dutch healthtech company has just made a move that could meaningfully shift how breast cancer screening is approached at scale. ScreenPoint Medical, headquartered in Nijmegen, Netherlands, has announced a total of $16 million in fresh funding — comprising $14 million from existing investors and an additional $2 million in non-dilutive research grants — to fuel the next generation of its artificial intelligence solutions for breast cancer detection and risk assessment. This latest round of AI funding news signals a growing confidence among institutional investors that clinical-grade AI in oncology is no longer a distant promise but an active, proven force in healthcare delivery.

The investment comes from long-standing backers, including global software investor Insight Partners and medical technology heavyweight Siemens Healthineers, both of whom have doubled down on their commitment to ScreenPoint's vision of personalised, precision-driven breast care. For the broader healthtech ecosystem, this is a compelling piece of AI funding news — not just because of the capital raised, but because of what it represents: the moment when AI-assisted radiology crosses over from research-stage promise to commercially validated, globally deployed reality.

What ScreenPoint Medical Actually Does

To understand why this round of AI funding matters, it helps to know what ScreenPoint Medical has built. The company is the creator of Transpara® Breast AI, a software platform that integrates directly with mammography systems — both 2D and 3D — to help radiologists detect suspicious regions in breast tissue and assess the likelihood of malignancy. The technology doesn't replace the radiologist; rather, it acts as a highly trained second pair of eyes, surfacing risk indicators that might otherwise be missed during high-volume screening workflows.

What sets Transpara apart from many other AI tools in the market is its evidence base. The platform is currently deployed across more than 30 countries, and to date, it has processed over 12 million mammograms. It is trusted by some of the world's leading hospitals, national screening programmes, academic medical centres, and large imaging groups. The platform holds both CE mark and FDA clearance for 2D and 3D mammography — two of the most rigorous regulatory bars in the global medical device industry — a factor that has significantly accelerated its institutional adoption.

The Research Momentum Behind the Funding

One of the more compelling aspects of this AI funding announcement is the timing. It arrives on the heels of a series of landmark clinical studies published in some of the world's most respected peer-reviewed journals, all of which centre on Transpara's real-world performance.

The most high-profile of these is the MASAI trial — the first-ever randomised controlled trial (RCT) of an AI tool in breast cancer screening. The results, published in The Lancet in January 2026, found "consistently favourable outcomes compared with standard double reading without AI," including measurable improvements in cancer detection rates and a meaningful reduction in radiologist workload. In the world of clinical research, an RCT is the gold standard — and having one validate AI-assisted mammography places ScreenPoint in a category that most competitors have not yet reached.

Alongside the MASAI findings, a separate prospective study published in Nature Medicine in March 2026 demonstrated that Transpara could enable what the research community is calling "autonomous AI triage" — a model where the software independently screens low-risk mammograms and excludes them from radiologist review. According to the findings, this approach could safely reduce mammography screening workload by as much as 63.6%, without compromising diagnostic accuracy. For healthcare systems buckling under staff shortages and rising screening volumes, that is a genuinely transformative number.

A third study, published in npj Digital Medicine in March 2026, evaluated ScreenPoint Medical's image-based breast cancer risk prediction algorithm against other leading solutions, including Mirai, iCAD, and Google's AI tool. The results showed that ScreenPoint's algorithm outperformed its peers in five-year breast cancer risk prediction. Within the top 14% of risk scores, the algorithm correctly predicted 41.8% of all future cancers and 50.3% of interval cancers — those that appear between routine screening cycles and are traditionally the hardest to catch. These are the kinds of numbers that don't just win publications; they win investor confidence.

Voices from the Boardroom: What Investors Are Saying

The language used by investors in this funding round is notable for its specificity and conviction — a far cry from the vague endorsements that often accompany early-stage AI funding news.

Pieter Kroese, CEO of ScreenPoint Medical, framed the round as a strategic endorsement rather than just a capital infusion. "This investment endorses our strategy and our shared success," he said. "We are well positioned to scale globally and accelerate the development of solutions that make care personal and powerful. Our goal is to support clinicians and women across the full continuum of breast cancer care." That phrase — "full continuum of breast cancer care" — is key to understanding what ScreenPoint is building toward: not just a screening tool, but an end-to-end platform covering prevention, detection, risk stratification, and treatment support.

From the Insight Partners side, Dr. Robert Epstein, MD, FACR, Health Care Senior Advisor, offered his perspective on the scale of the opportunity: "ScreenPoint Medical continues to lead and innovate in applying AI to breast imaging. The opportunity to create a greater level of personalised care is vast and clinically impactful at both a patient and population level. We are excited to support ScreenPoint Medical as it builds an integrated and comprehensive approach." For a firm like Insight Partners — which has backed ScreenPoint since at least its $28 million Series C round in 2021 — this renewed commitment underlines a long-term thesis that clinical AI in oncology is a durable market, not a cyclical hype wave.

Alexandra Krumbügel, Head of Product Line Women's Health at Siemens Healthineers, added her firm's rationale for re-investing: "Our continued investment reflects our strong conviction that AI will play a defining role in the future of breast imaging. This collaboration is driven by a shared focus on advancing breast cancer innovation and creating sustainable, long-term value for healthcare." The presence of Siemens Healthineers — one of the world's largest medical imaging companies — as a co-investor is strategically significant. It suggests not just financial backing, but potential for deeper product integration within Siemens' global imaging infrastructure.

What the Funding Will Be Used For

According to the company's announcement, the $16 million in AI funding will be directed across three core areas. The first is continued product innovation — building out Transpara's capabilities beyond screening and detection toward a broader, more integrated breast health platform that spans the entire patient journey, from initial risk screening through to post-diagnosis care support.

The second is international expansion. With the platform already deployed in 30+ countries, the company has a proven playbook for global scaling. New markets — particularly in Asia-Pacific and regions where breast cancer screening infrastructure is still developing — represent significant untapped opportunity. ScreenPoint's multi-language, multi-system compatibility makes it particularly well-suited for deployment in diverse healthcare environments.

The third area is strategic initiatives that consolidate ScreenPoint's position as a long-term partner within national health systems and major imaging networks. This includes continuing to participate in and sponsor landmark clinical trials — such as the PRISM Trial, a $16 million randomised study led by UCLA and UC Davis examining AI's role in improving mammography screening outcomes across the United States. Transpara was selected as the AI technology for that trial, the first large-scale study of its kind in the US.

The Broader Picture: AI Funding in MedTech Is Maturing

ScreenPoint Medical's raise arrives at a moment when AI funding in the medtech and healthtech sectors is maturing from a speculative phase into one defined by clinical proof and commercial traction. Investors are increasingly willing to deploy capital into AI health companies — but only those with peer-reviewed validation, regulatory clearances, and demonstrated real-world deployment at scale.

This AI funding news from ScreenPoint Medical checks all of those boxes. The company's trajectory — from early-stage AI research into a globally deployed clinical platform backed by Series C capital, strategic investors, and now a follow-on funding round — is a template that many other AI health companies are trying to replicate but few have achieved. The combination of Transpara's clinical evidence base, its installed base across 30+ countries, and the backing of investors like Insight Partners and Siemens Healthineers creates a competitive moat that is difficult to bridge quickly.

Looking ahead, the broader implications of this kind of AI funding news extend well beyond a single company. As AI tools like Transpara continue to demonstrate that they can reduce radiologist workload by more than 60%, predict future cancers with greater accuracy than competing platforms, and integrate seamlessly into existing clinical workflows, the case for national health systems to adopt AI-assisted screening becomes harder and harder to ignore. For women, that translates directly into earlier detection, more personalised risk management, and ultimately, better survival outcomes.